ATTR-CM (TRANSTHYRETIN AMYLOID CARDIOMYOPATHY)
Clinical trials for ATTR-CM (TRANSTHYRETIN AMYLOID CARDIOMYOPATHY) explained in plain language.
Never miss a new study
Get alerted when new ATTR-CM (TRANSTHYRETIN AMYLOID CARDIOMYOPATHY) trials appear
Sign up with your email to follow new studies for ATTR-CM (TRANSTHYRETIN AMYLOID CARDIOMYOPATHY), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
10-Year study monitors heart Drug's safety in Real-World use
Disease control OngoingThis study follows 110 adults in Korea taking Vyndamax capsules for a heart condition called ATTR-CM, where abnormal proteins build up in the heart. Researchers will track side effects and check how well the drug works over 10 years in everyday medical practice. The goal is to en…
Matched conditions: ATTR-CM (TRANSTHYRETIN AMYLOID CARDIOMYOPATHY)
Sponsor: Pfizer • Aim: Disease control
Last updated May 18, 2026 12:01 UTC
-
German health data study sheds light on rare heart condition ATTR-CM
Knowledge-focused OngoingThis study looks at anonymous health insurance records from Germany to learn more about a rare heart disease called ATTR-CM. Researchers want to see how long people live after diagnosis, how often they are hospitalized, and how common the disease is. No new treatments or visits a…
Matched conditions: ATTR-CM (TRANSTHYRETIN AMYLOID CARDIOMYOPATHY)
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated May 26, 2026 12:00 UTC